IXICO CEO Giulio Cerroni presents new Huntingdon’s disease trial contract



Published
IXICO PLC's CEO Giulio Cerroni talks to Proactive about striking another deal with a leading global pharma company to support the company's ongoing drug development programme in Huntington's disease (HD).

Under the new contract, which is worth around £2.1mln, IXICO will provide services to support the phase II dose-finding study to explore safety, biomarkers and efficacy of the investigative drug in over 300 participants with early manifest and prodromal HD.

Cerroni references a presentation (here: https://chdifoundation.org/) aimed at non-scientists that convey the major themes, scientific breakthroughs, and clinical trial updates from each year’s Huntington’s Disease Therapeutics Conference held (most usually) in Palm Springs, California.
Category
Health
Be the first to comment